Published in AIDS Weekly, November 21st, 2005
The first-quarter fiscal-2006 results included a $4.5 million pretax gain from the sale of an investment. The first-quarter fiscal-2005 results included a $4.5 million pretax charge related to the discontinuation of most of the operations of Paracel. All per share amounts refer to Applera Corp.-Celera Genomics Group common stock.
"Celera Genomics made notable progress during the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.